详细信息
敦煌重灸联合温通针法治疗脾肾阳虚型多囊卵巢综合征不孕症的临床研究 被引量:1
Clinical study of Dunhuang heavy moxibustion combined with warming and dredging acupuncture in the treatment of infertility of polycystic ovary syndrome with spleen-kidney Yang deficiency syndrome
文献类型:期刊文献
中文题名:敦煌重灸联合温通针法治疗脾肾阳虚型多囊卵巢综合征不孕症的临床研究
英文题名:Clinical study of Dunhuang heavy moxibustion combined with warming and dredging acupuncture in the treatment of infertility of polycystic ovary syndrome with spleen-kidney Yang deficiency syndrome
作者:范娥[1];杨丽娜[1];崔未霞[1];魏巧玲[1];刘娟娟[1];罗彩凤[1];杨艳娥[1]
第一作者:范娥
机构:[1]甘肃中医药大学附属医院北院针灸科,甘肃兰州730200
第一机构:甘肃中医药大学第二附属医院
年份:2023
卷号:24
期号:9
起止页码:1017
中文期刊名:山西中医药大学学报
外文期刊名:Journal of Shanxi University of Chinese Medicine
基金:甘肃省科技计划项目(自然科学基金)(22JR5RA613);兰州市卫生健康科技发展项目(2019-049)。
语种:中文
中文关键词:多囊卵巢综合征不孕症;敦煌重灸;温通针法;脾肾阳虚型
外文关键词:polycystic ovary syndrome;Dunhuang heavy moxibustion;warming and dredging acupuncture;spleen-kidney Yang deficiency syndrome
摘要:目的:观察敦煌重灸联合温通针法治疗脾肾阳虚型多囊卵巢综合征不孕症的临床疗效。方法:将2019年6月—2021年12月就诊于甘肃中医药大学附属医院北院针灸科、妇产科门诊及住院的脾肾阳虚型多囊卵巢综合征不孕症患者36例,按照就诊顺序随机分为治疗组与对照组,每组18例。对照组于月经第5天开始口服克罗米芬50 mg(1片/d),连续5 d。治疗组自月经第5天开始给予敦煌重灸联合温通针法,隔日1次;1个月经周期为1个疗程,直到下次月经来潮停止针灸。如果监测提示患者无排卵,将克罗米芬增加至100 mg(2片/d),最大剂量150 mg(3片/d),两组均治疗6个疗程。比较两组患者症状、性激素水平[促卵泡激素(FSH)、黄体生成素(LH)、雌二醇(E_(2))、睾酮(T)、催乳素(PRL)]及优势卵泡直径。结果:治疗6个疗程后两组患者症状、性激素水平(FSH、LH、E_(2)、T、PRL)及优势卵泡直径与治疗前相比,差异有统计学意义(P<0.05)。治疗后治疗组患者的症状、性激素水平(FSH、LH、E_(2)、T、PRL)及优势卵泡直径与对照组相比,差异有统计学意义(P<0.05)。治疗6个疗程后治疗组受孕率为61.11%,对照组受孕率为44.44%,两组相比,差异有统计学意义(P<0.05)。结论:敦煌重灸联合温通针法治疗脾肾阳虚型多囊卵巢综合征不孕症疗效确切,同时使用的医疗资源极少,对人体无毒副作用,是一种真正意义上的“绿色”疗法,为临床研究提供可靠的循证医学依据。
Objective:To observe the clinical efficacy of Dunhuang heavy moxibustion combined with warming and dredg-ing acupuncture in the treatment of infertility of polycystic ovary syndrome with spleen-kidney Yang deficiency syndrome.Meth-ods:A total of 36 infertility patients with polycystic ovary syndrome with spleen-kidney Yang deficiency syndrome who were admitted to the Department of Acupuncture and Moxibustion,Obstetrics and Gynecology Clinic and Impatient Department,North Hospital of Gansu University of Chinese Medicine from June 2019 to December 2021 were randomly divided into treatment group and control group according to the order of treatment,with 18 cases in each group.The patients in the control group took clomiphene 50 mg(1 tablet/d)orally on the 5th day of menstruation for 5 consecutive days.The patients in the treatment group were given Dunhuang heavy moxibustion combined with warming and dredging acupuncture from the 5th day of menstruation,once every other day;1 menstrual cycle for 1 course of treatment,until the next menstrual period to stop acupuncture.If the monitoring result indicated anovulation,clomiphene was increased to 100 mg(2 tablets/day)with a maximum dose of 150 mg(3 tablets/day).The patients in both groups were treated for 6 courses.Symptoms,sex hormone levels(follicle-stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E_(2)),testosterone(T),prolactin(PRL))and dominant follicle diameter were compared between the two groups.Results:After 6 courses of treatment,there were significant differences in symptoms,sex hormone levels(FSH,LH,E_(2),T,PRL)and dominant follicle diameter between the two groups compared with those before treatment,and the difference was statistically significant(P<0.05).After treatment,the symptoms,sex hormone levels(FSH,LH,E_(2),T,PRL)and dominant follicle diameter in the treatment group were significantly different from those in the control group,and the difference was statistically significant(P<0.05).After 6 courses of treatment,the pregnancy rate in the treatment group was 61.11%,and that in the control group was 44.44%.The difference between the two groups was statistically significant(P<0.05).Conclusion:Dunhuang heavy moxibustion combined with warming and dredging acupuncture in the treatment of infertility of polycystic ovary syndrome with spleen-kidney Yang deficiency syndrome has definite curative effect,and it uses few medical resources and has no toxic side effects on human body.It is a true“green”therapy,which can provide reliable evidence-based medical basis for clinical research.
参考文献:
正在载入数据...